Home » Stocks » LEGN

Legend Biotech Corporation (LEGN)

Stock Price: $27.18 USD -0.30 (-1.09%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $27.18 +0.00 (0.01%) Feb 26, 4:31 PM
Market Cap 3.51B
Revenue (ttm) 57.26M
Net Income (ttm) -132.97M
Shares Out 258.70M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $27.18
Previous Close $27.48
Change ($) -0.30
Change (%) -1.09%
Day's Open 26.68
Day's Range 25.81 - 27.46
Day's Volume 309,081
52-Week Range 24.60 - 43.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 1 week ago

Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.

Other stocks mentioned: AVIR, JNJ, LLY, NKTX, RHHBY, RNA
Business Wire - 3 weeks ago

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of nov...

Business Wire - 2 months ago

SOMERSET, N.J.--(BUSINESS WIRE)-- #LegendBiotech--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and d...

Seeking Alpha - 2 months ago

Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutra...

Other stocks mentioned: ABBV, ADCT, ALLO, BNTX, YMAB
Business Wire - 2 months ago

SOMERSET, N.J.--(BUSINESS WIRE)-- #JPM2021--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and develop...

Business Wire - 2 months ago

SOMERSET, N.J.--(BUSINESS WIRE)-- #biotech--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and develop...

Business Wire - 2 months ago

SOMERSET, N.J.--(BUSINESS WIRE)-- #LYMSM--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and developme...

The Motley Fool - 2 months ago

Targeting BCMA is all the rage, but who will come out on top?

Other stocks mentioned: BLUE, BMY, JNJ, REGN
The Motley Fool - 2 months ago

Drugmakers are targeting B-cell maturation antigen in different ways.

Other stocks mentioned: BLUE, BMY, JNJ, REGN
Business Wire - 2 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of nov...

Business Wire - 2 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of nov...

Business Wire - 3 months ago

SOMERSET, N.J.--(BUSINESS WIRE)-- #ASH20--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech) today announced that it will host a virtual Key Opinion Leader (KOL) event on Monday, Decem...

Business Wire - 3 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of nov...

Business Wire - 3 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global clinical-stage biopharmaceutical company engaged in the discovery and d...

Business Wire - 3 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of nov...

Business Wire - 3 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel...

Newsfile Corp - 3 months ago

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Legend Bio To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfil...

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - October 22, 2020) - Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend" or "the Company") (...

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - October 8, 2020) -  Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims aga...

Business Wire - 4 months ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $LEGN #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Legend Biotech Corporation (LEGN) on Behalf of Investors

Business Wire - 4 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel...

Newsfile Corp - 5 months ago

New York, New York--(Newsfile Corp. - September 26, 2020) -  Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of sharehold...

Newsfile Corp - 5 months ago

Los Angeles, California--(Newsfile Corp. - September 25, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inve...

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Legend Biotech Corporation ...

Business Wire - 5 months ago

LOS ANGELES--(BUSINESS WIRE)---- $LEGN #CLASSACTION--Glancy Prongay & Murray LLP Continues Investigation on Behalf of Legend Biotech Corporation Investors (LEGN)

Zacks Investment Research - 5 months ago

Legend Biotech (LEGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Business Wire - 5 months ago

LOS ANGELES--(BUSINESS WIRE)---- $LEGN #classaction--The Law Offices of Frank R. Cruz announces an investigation of Legend Biotech Corporation (“Legend” or the “Company”) (NASDAQ: LEGN) on beh...

Business Wire - 5 months ago

LOS ANGELES--(BUSINESS WIRE)---- $LEGN #LEGN--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Legend Biotech Corporation

Business Wire - 5 months ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $LEGN #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Legend Biotech Corporation (LEGN) on Behalf of Investors

Business Wire - 5 months ago

LOS ANGELES--(BUSINESS WIRE)---- Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Legend...

Business Wire - 5 months ago

ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN) complied with federal securities laws. On ...

Business Wire - 5 months ago

LOS ANGELES--(BUSINESS WIRE)---- $LEGN #LEGN--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Legend Biotech Corporation.

The Motley Fool - 5 months ago

A customs investigation is sending this Chinese biotech stock lower today.

Business Wire - 5 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global, clinical-stage biopharmaceutical company engaged in the discovery and development of no...

Business Wire - 5 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel...

Business Wire - 5 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel...

Business Wire - 6 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ:LEGN) announced today that the China Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA) has re...

Business Wire - 6 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel...

Business Wire - 6 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech (NASDAQ: LEGN) today announced preliminary results for the first half of 2020.

Forbes - 8 months ago

“Johnson & Johnson has deep roots in China with an innovation footprint dating back nearly four decades,” Chief Science Officer Paul Stoffels said last year.

The Motley Fool - 8 months ago

Pandemic-driven enthusiasm for biotech made this a great time for its initial public offering.

About LEGN

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy that targets the B-cell maturation antigen. The company is conducting multiple clinical trials to evaluate LCAR-B38M/JNJ-4528 as an earlier line of therapy for multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in Revlimid-refractory MM. It also has ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 5, 2020
CEO
Dr. Ying Huang
Employees
800
Stock Exchange
NASDAQ
Ticker Symbol
LEGN
Full Company Profile

Financial Performance

In 2019, Legend Biotech's revenue was $57.26 million, an increase of 16.55% compared to the previous year's $49.13 million. Losses were -$132.97 million, 4,676.3% more than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Legend Biotech stock is "Buy." The 12-month stock price forecast is 50.67, which is an increase of 86.42% from the latest price.

Price Target
$50.67
(86.42% upside)
Analyst Consensus: Buy